Evidence map›Paper›PMID 41892176›Full record

ReviewCurrent oncology (Toronto, Ont.)2026

Unlocking

Austin Frisch, Eric Martin, Timothy Cannon, Raymond Wadlow, Srivatsan Raghavan, Triparna Sen, Nagla Abdel Karim

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Austin FrischInova Fairfax Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA 22042, USA.
Eric MartinInova Fairfax Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA 22042, USA.
Timothy CannonInova Schar Cancer Center, Inova Fairfax Hospital, Fairfax, VA 22042, USA.
Raymond WadlowInova Schar Cancer Center, Inova Fairfax Hospital, Fairfax, VA 22042, USA.
Srivatsan RaghavanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-5374-9918
Triparna SenDepartment of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Nagla Abdel KarimGeorge Washington (GW) Cancer Center, Washington, DC 20037, USA.

Funding

Regulation and targeting of tumor cell states and plasticity in pancreatic cancerK08CA260442 · NCI · DANA-FARBER CANCER INST · PI Srivatsan Raghavan · 2022 to 2026
$1.5M
NCI NIH HHS K08 CA260442
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gastrointestinal NeoplasmsProto-Oncogene Proteins p21(ras)HumansMolecular Targeted TherapyMutationKRAS protein, humanProto-Oncogene Proteins p21(ras)colorectal cancergastrointestinal malignancyKRASpancreatic cancerresistance

Identifiers

PMID41892176
PMCPMC13024909

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.